GOSERELIN ACETATE FOR RECURRENT ENDOMETRIOSIS

Maha Ak Al-Azzawy
In: The Iraqi Journal of Medical Sciences, Vol 10, Iss 1 (2016) · 2012 · vol. 10(1) · W3083754919
article OA: green CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy Full text JSON View on OpenAlex
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Goserelin acetate depot administered monthly for six months improved symptoms and ultrasound findings in 90% and 80% of patients with recurrent endometriosis, respectively, with a 20% recurrence rate after one year.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background: Endometriosis is a chronic and recurrent disease characterized by the presence and proliferation of functional endometrial glands and stroma outside the uterine cavity. GnRH analogues are currently one of the most widely used medical therapies for endometriosis. Objective:This study assesses the role of zoladex (goserelin acetate depot) for patients with recurrent endometriosis after surgical treatment. Methods: A descriptive follow up study of 20 women with recurrent endometriosis after surgery were arranged to receive Goserelin acetate (Zoladex) one month depot administered subcutaneously monthly for a period of six months followed by one year follow up in AL- Karama Teaching Hospital -Wasit Governorate/ Iraq from May 2008 until May 2010. Results:Ninety percent of patients showed symptomatic improvement, ultrasound improvement achieved in 80%, recurrence rate of 20% within one year after stopping treatment and none of the patients required surgical interference during the period of the study. Conclusions:Our results support the beneficial role of Goserelin acetate (3.6 mg) month depot administered subcutaneously in the treatment of recurrent endometriosis after surgery. Keywords :Endometriosis, GnRH analogues, Goserelin acetate
Full text 1,365 characters · extracted from oa-html · click to expand
The Iraqi Journal of Medical Sciences (Apr 2016) GOSERELIN ACETATE FOR RECURRENT ENDOMETRIOSIS Abstract Background: Endometriosis is a chronic and recurrent disease characterized by the presence and proliferation of functional endometrial glands and stroma outside the uterine cavity. GnRH analogues are currently one of the most widely used medical therapies for endometriosis. Objective:This study assesses the role of zoladex (goserelin acetate depot) for patients with recurrent endometriosis after surgical treatment. Methods: A descriptive follow up study of 20 women with recurrent endometriosis after surgery were arranged to receive Goserelin acetate (Zoladex) one month depot administered subcutaneously monthly for a period of six months followed by one year follow up in AL- Karama Teaching Hospital -Wasit Governorate/ Iraq from May 2008 until May 2010. Results:Ninety percent of patients showed symptomatic improvement, ultrasound improvement achieved in 80%, recurrence rate of 20% within one year after stopping treatment and none of the patients required surgical interference during the period of the study. Conclusions:Our results support the beneficial role of Goserelin acetate (3.6 mg) month depot administered subcutaneously in the treatment of recurrent endometriosis after surgery. Keywords :Endometriosis, GnRH analogues, Goserelin acetate

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (12)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK